Both the soluble and particulate fractions of cells contain guanylate cyclase (also known as guanylyl cyclase, or GC), which catalyzes the formation of cGMP from GTP. Guanylyl cyclases send out signals by making cGMP, the second messenger.
Particulate GC (pGC) and a soluble GC (sGC) activated by nitric oxide make up the GC family. (pGC-A to pGC-G) Seven pGC isoforms have so far been identified. Peptide ligands that bind to the extracellular domains of pGCs activate them. The core enzyme in the nitric oxide signal transduction pathway, sGC, is a receptor for endogenous and exogenous nitric oxide and is activated several times upon its binding. Vasodilation, smooth muscle relaxation, and platelet aggregation are just a few of the significant physiologic responses that are triggered by the second messenger cGMP, which is produced by sGC.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3934 | PLECANATIDE | 467426-54-6 | Plecanatide (Trade name Trulance; formerly SP304; SP-304), a 16 amino acid peptide and a synthetic analog of uroguanylin, is a drug approved by FDA for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. |
|
V33986 | Plecanatide acetate | 1075732-84-1 | Plecanatide acetate, the acetate salt of plecanatide, is a guanylate cyclase-C (GC-C) receptor agonist with anti-inflammatory activity. In T84 cells, it activates GCC with an EC50 of 190 nM. |
|
V1868 | Riociguat (BAY 63-2521) | 625115-55-1 | Riociguat (formerly also known as BAY-63-2521, BAY-632521; trade name Adempas) is a first-in-class and oral bioavailable soluble guanylate cyclase (GC) stimulator that has been approved to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). |
|
V4207 | Vericiguat | 1350653-20-1 | Vericiguat (formerly BAY-1021189; BAY10-21189; Verquvo) is an orally bioavailable and potent soluble guanylate cyclase (sGC) stimulator that has been approved in 2021 by FDA to reduce the risk of cardiovascular death and heart failure (HF). |
|
V74638 | Zagociguat | 2201048-82-8 | Zagociguat is a stimulator of soluble guanylate cyclase. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
